EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Busting the Breast Cancer with AstraZeneca’s Gefitinib

S Chemmalar iD, A R Intan Shameha iD, Che Azurahanim Che Abdullah iD, Nor Asma Ab Razak iD, Loqman Mohamad Yusof, Mokrish Ajat iD, Kim Wei Chan iD, Md Zuki Abu Bakar Zakaria iD

Advances in Pharmacological and Pharmaceutical Sciences · 04.12.2023 · 2023 · 1-26

DOI: 10.1155/2023/8127695 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Pharmacological and Pharmaceutical Sciences, erschienen am 04.12.2023. Verfasst von S Chemmalar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Anatomy, Veterinary College and Research Institute, Tamil Nadu Veterinary and Animal Sciences University (TANUVAS), Theni 62…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education, Malaysia.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most common cancer diagnosed in women, and in 2020, there were 684, 996 deaths due to this disease. Epidermal growth factor receptors (EGFRs) and their respective ligands have been blamed for the pathogenesis and resistance to treatment in specific breast cancer cases. With EGFR having four homologues: EGFR1, EGFR2, EGFR3, and EGFR4, in-depth understanding of EGFR biology led to the discovery of small-molecule inhibitors and antibodies against this receptor. Gefitinib (GEF), a tyrosine kinase inhibitor of EGFR1, possesses a vast potential for treatment against breast cancer and is supported by a multiplicity of experiments. Unfortunately, in clinical trials, GEF did not show the outcomes expected with complete response and disease progress. This is due to incomplete understanding of the molecular mechanisms involved in EGFR signaling and endocrine sensitivity. Hence, additional in-depth experiments are needed regarding various molecular pathways and crosstalk pathways to comprehend GEF’s action mechanism thoroughly in breast cancer patients. In this review, the role of EGFR in the development and pathogenesis of breast cancer and the pharmacokinetics and pharmacotherapy of GEF for the treatment of breast cancer have been elaborated. Nanomedicines synthesized with GEF have shown positive experimental response, paving a promising path for GEF against breast cancer.

Autor:innen und Institutionen

  • Department of Veterinary Anatomy, Veterinary College and Research Institute, Tamil Nadu Veterinary and Animal Sciences University (TANUVAS), Theni 625534, Tamil Nadu, India.
  • Natural Medicines and Products Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia.
  • Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, UPM, Serdang 43400, Selangor, Malaysia.
  • Biophysics Laboratory, Department of Physics, Faculty of Science, Laboratory of Cancer Research (MAKNA), Institute of Bioscience and Material Synthesis & Characterization Laboratory, Institute of Advanced Technology, UP…
  • Department of Companion Animal Medicine and Surgery, Faculty of Veterinary Medicine, UPM, Serdang 43400, Selangor, Malaysia.
  • Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine and Natural Medicines and Product Research Laboratory, Institute of Bioscience, UPM, Serdang 43400, Selangor, Malaysia.

ORCID-Profile: S Chemmalar, A R Intan Shameha, Che Azurahanim Che Abdullah, Nor Asma Ab Razak, Mokrish Ajat, Kim Wei Chan, Md Zuki Abu Bakar Zakaria

Förderung

  • Ministry of Higher Education, Malaysia

Zitieren

APA

Chemmalar, S., Intan Shameha, A. R., Che Abdullah, C. A., Ab Razak, N. A., Yusof, L. M., Ajat, M., Chan, K. W., & Abu Bakar Zakaria, M. Z. (2023). Busting the Breast Cancer with AstraZeneca’s Gefitinib. Advances in Pharmacological and Pharmaceutical Sciences, 2023, 1-26. https://doi.org/10.1155/2023/8127695

Vancouver

Chemmalar S, Intan Shameha AR, Che Abdullah CA, Ab Razak NA, Yusof LM, Ajat M, et al. Busting the Breast Cancer with AstraZeneca’s Gefitinib. Advances in Pharmacological and Pharmaceutical Sciences. 2023;2023:1-26. doi:10.1155/2023/8127695

BibTeX
@article{Chemmalar2023,
  author = {Chemmalar, S and Intan Shameha, A R and Che Abdullah, Che Azurahanim and Ab Razak, Nor Asma and Yusof, Loqman Mohamad and Ajat, Mokrish and Chan, Kim Wei and Abu Bakar Zakaria, Md Zuki},
  title = {Busting the Breast Cancer with AstraZeneca’s Gefitinib},
  journal = {Advances in Pharmacological and Pharmaceutical Sciences},
  year = {2023},
  volume = {2023},
  pages = {1--26},
  doi = {10.1155/2023/8127695}
}
Kostenlos starten →